Revenue
No reported data
Greenwich LifeSciences, Inc. (GLSI)
Price—Loading quote
Net income
2019
2020
2021
2022
2023
2024
2025
Free cash flow
No reported data
Total cash / debt
CashTotal debt
2018
2019
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|---|---|
| Research & development | $17.2M | $15.5M | $7.7M | $6.5M | $3.6M | $1.1M | $2.6M |
| Operating expenses | $19.4M | $17.6M | $9.3M | $8.0M | $4.6M | $1.9M | $3.4M |
| Operating income | −$19.4M | −$17.6M | −$9.3M | −$8.0M | −$4.6M | −$1.9M | −$3.4M |
| Net income | −$19.4M | −$17.4M | −$8.9M | −$7.8M | −$4.6M | −$1.9M | −$3.4M |
| Basic EPSper diluted share | -$1.43 | -$1.34 | -$0.69 | -$0.61 | -$0.35 | -$0.20 | -$1.52 |
| Diluted EPSper diluted share | -$1.43 | -$1.34 | -$0.69 | -$0.61 | -$0.35 | -$0.20 | -$1.52 |
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| Jan 13, 2026Form 4 | Patel SnehalCEO and CFO | BuyCommon Stock | 1.8K | $29.83 | $53.7K | 5.60M |
| Jan 12, 2026Form 4 | Patel SnehalCEO and CFO | BuyCommon Stock | 2.9K | $27.54 | $79.9K | 5.60M |
| Dec 31, 2025Form 4 | Patel SnehalCEO and CFO | BuyCommon Stock | 4.3K | $21.36 | $91.8K | 5.60M |
| Dec 30, 2025Form 4 | Patel SnehalCEO and CFO | BuyCommon Stock | 2.9K | $21.73 | $63.0K | 5.60M |
| Dec 18, 2025Form 4 | Patel SnehalCEO and CFO | BuyCommon Stock | 4.1K | $12.62 | $51.7K | 5.59M |